CN1604892A - D-脯氨酸的前药 - Google Patents
D-脯氨酸的前药 Download PDFInfo
- Publication number
- CN1604892A CN1604892A CNA028249348A CN02824934A CN1604892A CN 1604892 A CN1604892 A CN 1604892A CN A028249348 A CNA028249348 A CN A028249348A CN 02824934 A CN02824934 A CN 02824934A CN 1604892 A CN1604892 A CN 1604892A
- Authority
- CN
- China
- Prior art keywords
- tetramethyleneimine
- compound
- caproyl
- oxo
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
实施例编号 | 大鼠微粒体 | 人微粒体 | 大鼠血浆t1/2(小时) | ||
清除率 | MAB% | 清除率 | MAB%90 | ||
1 | 5 | 88 | 1 | 93 | 0.4 |
2 | 18 | 66 | 64 | 20 | 低 |
3 | 82 | 30 | 16 | 50 | 低 |
4 | 625 | 5 | 57 | 22 | 低 |
5 | 36 | 50 | 8 | 67 | 低 |
6 | 7 | 84 | 1 | 96 | 0.8 |
7 | 9 | 73 | 2 | 90 | 0.2 |
10 | 9 | 79 | 2 | 90 | 1.3 |
11 | 46 | 44 | 5 | 77 | 0.4 |
12 | 253 | 12 | 73 | 18 |
Claims (17)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01129793.4 | 2001-12-14 | ||
EP01129793 | 2001-12-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1604892A true CN1604892A (zh) | 2005-04-06 |
CN100368397C CN100368397C (zh) | 2008-02-13 |
Family
ID=8179542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028249348A Expired - Fee Related CN100368397C (zh) | 2001-12-14 | 2002-12-06 | D-脯氨酸的前药 |
Country Status (26)
Country | Link |
---|---|
US (1) | US6903129B2 (zh) |
EP (2) | EP1458680A1 (zh) |
JP (1) | JP4192100B2 (zh) |
KR (1) | KR100678785B1 (zh) |
CN (1) | CN100368397C (zh) |
AR (1) | AR038010A1 (zh) |
AU (1) | AU2002361982B2 (zh) |
BR (1) | BR0214932A (zh) |
CA (1) | CA2470037C (zh) |
GT (1) | GT200200275A (zh) |
HK (1) | HK1076100A1 (zh) |
HR (1) | HRP20040494A2 (zh) |
HU (1) | HUP0402600A3 (zh) |
IL (2) | IL162158A0 (zh) |
MX (1) | MXPA04005693A (zh) |
MY (1) | MY129431A (zh) |
NO (1) | NO20042979L (zh) |
NZ (1) | NZ533188A (zh) |
PA (1) | PA8561201A1 (zh) |
PE (1) | PE20030764A1 (zh) |
PL (1) | PL370803A1 (zh) |
RU (1) | RU2305679C2 (zh) |
TW (1) | TWI225400B (zh) |
UY (1) | UY27584A1 (zh) |
WO (1) | WO2003051836A1 (zh) |
ZA (1) | ZA200404546B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106459016A (zh) * | 2014-04-29 | 2017-02-22 | 葛兰素史密斯克莱知识产权发展有限公司 | 1,1’‑(1,6‑二氧代‑1,6‑己二基)双‑d‑脯氨酸的前药 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0313386D0 (en) * | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
RU2530601C2 (ru) * | 2012-10-05 | 2014-10-10 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Ингибитор образования цинк-зависимых димеров бета-амилоида |
US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
GB201518950D0 (en) * | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
WO2017072090A1 (en) * | 2015-10-27 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
GB202111866D0 (en) | 2021-08-18 | 2021-09-29 | Ucl Business Plc | Prodrugs for use in the treatment of tissue damage |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
EP0915088B1 (en) * | 1997-10-31 | 2002-09-18 | F. Hoffmann-La Roche Ag | D-Proline derivatives |
-
2002
- 2002-12-02 US US10/307,699 patent/US6903129B2/en not_active Expired - Lifetime
- 2002-12-06 IL IL16215802A patent/IL162158A0/xx unknown
- 2002-12-06 AU AU2002361982A patent/AU2002361982B2/en not_active Ceased
- 2002-12-06 KR KR1020047009036A patent/KR100678785B1/ko not_active IP Right Cessation
- 2002-12-06 PL PL02370803A patent/PL370803A1/xx not_active Application Discontinuation
- 2002-12-06 CN CNB028249348A patent/CN100368397C/zh not_active Expired - Fee Related
- 2002-12-06 WO PCT/EP2002/013827 patent/WO2003051836A1/en not_active Application Discontinuation
- 2002-12-06 EP EP02796578A patent/EP1458680A1/en not_active Withdrawn
- 2002-12-06 EP EP06020711A patent/EP1743884A1/en not_active Withdrawn
- 2002-12-06 NZ NZ533188A patent/NZ533188A/en not_active IP Right Cessation
- 2002-12-06 RU RU2004121783/04A patent/RU2305679C2/ru not_active IP Right Cessation
- 2002-12-06 JP JP2003552723A patent/JP4192100B2/ja not_active Expired - Fee Related
- 2002-12-06 HU HU0402600A patent/HUP0402600A3/hu unknown
- 2002-12-06 BR BR0214932-0A patent/BR0214932A/pt not_active Application Discontinuation
- 2002-12-06 MX MXPA04005693A patent/MXPA04005693A/es active IP Right Grant
- 2002-12-06 CA CA2470037A patent/CA2470037C/en not_active Expired - Fee Related
- 2002-12-10 PE PE2002001184A patent/PE20030764A1/es not_active Application Discontinuation
- 2002-12-11 TW TW091135829A patent/TWI225400B/zh not_active IP Right Cessation
- 2002-12-11 PA PA20028561201A patent/PA8561201A1/es unknown
- 2002-12-12 AR ARP020104818A patent/AR038010A1/es unknown
- 2002-12-13 MY MYPI20024679A patent/MY129431A/en unknown
- 2002-12-13 UY UY27584A patent/UY27584A1/es not_active Application Discontinuation
- 2002-12-13 GT GT200200275A patent/GT200200275A/es unknown
-
2004
- 2004-05-24 IL IL162158A patent/IL162158A/en not_active IP Right Cessation
- 2004-06-01 HR HR20040494A patent/HRP20040494A2/hr not_active Application Discontinuation
- 2004-06-08 ZA ZA200404546A patent/ZA200404546B/en unknown
- 2004-07-13 NO NO20042979A patent/NO20042979L/no not_active Application Discontinuation
-
2005
- 2005-09-16 HK HK05108123A patent/HK1076100A1/xx not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106459016A (zh) * | 2014-04-29 | 2017-02-22 | 葛兰素史密斯克莱知识产权发展有限公司 | 1,1’‑(1,6‑二氧代‑1,6‑己二基)双‑d‑脯氨酸的前药 |
CN106459016B (zh) * | 2014-04-29 | 2019-11-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 1,1’-(1,6-二氧代-1,6-己二基)双-d-脯氨酸的前药 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1615144A (zh) | 治疗神经脑血管疾病的组合物 | |
CN1231478C (zh) | 光学活性的哌啶中间体的制备方法和该中间体 | |
CN1036393C (zh) | 7-(2-氨乙基)-苯并噻唑酮 | |
CN1688544A (zh) | 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6-二取代的氮杂双环(3.1.0)己烷衍生物 | |
CN1930127A (zh) | 用于合成cxcr4拮抗剂的方法 | |
CN1092652C (zh) | 2-咪唑啉基氨基吲哚化合物及含有它的组合物和应用 | |
CN1104422C (zh) | 用作α-2肾上腺素能受体兴奋剂的胍基杂环化合物 | |
CN1124960A (zh) | 作为5-ht/a和/或5-ht2配体的吲哚衍生物 | |
CN1080925A (zh) | 吡嗪并吲哚 | |
CN1032785A (zh) | L-二羟基苯丙氨酸衍生物或其酸加成盐、其生产方法及其用途 | |
CN1226248A (zh) | 用于抑制细胞增殖的取代的双吲哚基马来酰亚胺 | |
CN1990482A (zh) | 一类新型的二氢黄酮醇类化合物及其制备方法和用途 | |
CN1604892A (zh) | D-脯氨酸的前药 | |
CN1556800A (zh) | 西酞普兰的制备方法 | |
CN1034366A (zh) | 非肽的血管紧张肽原酶抑制剂 | |
CN1294588A (zh) | 螺哌啶衍生物 | |
CN1272340C (zh) | 齐墩果酸偶联衍生物及其药物用途 | |
CN1092074A (zh) | 二氮杂䓬衍生物 | |
CN88100478A (zh) | 烷基褪黑激素 | |
CN1227230C (zh) | Nmda受体配体的前药 | |
CN1016169B (zh) | 制备药用咪唑衍生物的方法 | |
CN87103528A (zh) | 1,3-二取代的咪唑盐类 | |
CN1774414A (zh) | 用于溶解可溶性差的分子的新型非离子表面活性剂 | |
CN1023479C (zh) | 乙二胺的单酰胺衍生物的制备方法 | |
CN1239944A (zh) | 季戊四醇的新衍生物、其制备方法和用途以及用于合成它的中间体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1076100 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1076100 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: PENGTESSIN TREATMENT CO., LTD. Free format text: FORMER OWNER: FO HUFFMAM-LAROCHE CO., LTD. Effective date: 20100611 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: BASILEA, SWITZERLAND TO: LONDON, THE UNITED KINGDOM |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100611 Address after: London, England Patentee after: Bloomberg therapy Ltd Address before: Basel Patentee before: F. Hoffmann-La Roche AG |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080213 Termination date: 20131206 |